NCT04069273View on ClinicalTrials.gov

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

June 11, 2026

Study Completion Date

December 10, 2026

Conditions
Gastric CancerGastroEsophageal CancerAdenocarcinoma
Interventions
DRUG

Pembrolizumab Monotherapy

Pembrolizumab 200 mg IV

DRUG

Ramucirumab

Ramucirumab 10 mg/kg IV

DRUG

Paclitaxel

Paclitaxel 90 mg/m2 IV

Trial Locations (2)

53226

RECRUITING

Froedtert and The Medical College of Wisconsin, Milwaukee

55905

RECRUITING

Mayo Clinic- Minnesota, Rochester

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Mayo Clinic

OTHER

lead

Harry H Yoon

OTHER